The delivery of N-myc downstream-regulated gene 2 (NDRG2) self-amplifying mRNA via modified lipid nanoparticles as a potential treatment for drug-resistant and metastatic cancers release_cufgxrj45jeipldxyfgo2ysajm

by Sandra Reznik, Amit K. Tiwari, Vivek Chavda, Charles R. Ashby Jr

Published in Medical Review by Walter de Gruyter GmbH.

2024   Volume 0, Issue 0, p235-238

Abstract

<jats:title>Abstract</jats:title> The protein, N-myc downstream-regulated gene 2 (NDRG2), a tumor suppressor, is significantly decreased or absent in many types of cancer. There is a significant negative correlation between the levels of NDRG2 and the development and progression of cancer tumor recurrence and tumor invasion, in different cancers. In contrast, the <jats:italic>in vitro</jats:italic> and <jats:italic>in vivo</jats:italic> overexpression of the NDRG2 protein decreases the proliferation, growth, adhesion and migration of many types of cancer cells. The <jats:italic>in vitro</jats:italic> overexpression of NDRG2 increases the efficacy of certain anticancer drugs in specific types of cancer cells. We hypothesize that the delivery of the mRNA of the NDRG2 protein, encapsulated by lipid nanoparticles, could represent a potential treatment of metastatic and drug-resistant cancers. This would be accomplished using a self-amplifying mRNA that encodes the NDRG2 protein and an RNA-dependent-RNA polymerase, obtained from an <jats:italic>in vitro</jats:italic>transcribed (IVT) mRNA. The IVT mRNA would be encapsulated in a lipid nanoformulation. The efficacy of the nanoformulation would be determined in cultured cancer cells and if the results are positive, nude mice transplanted with either drug-resistant or metastatic drug-resistant cancer cells, would be treated with the nano- formulation and monitored for efficacy and adverse effects. If the appropriate preclinical studies indicate this formulation is efficacious and safe, it is possible it could be evaluated in clinical trials.
In application/xml+jats format

Archived Files and Locations

application/pdf   874.2 kB
file_2mf2nwhqmvauzlqyv7lnt72j6a
www.degruyter.com (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2024-04-01
Language   en ?
Container Metadata
Not in DOAJ
Not in Keepers Registry
ISSN-L:  2749-9642
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 6be3f5e5-1f5c-4cff-a56f-0b65d2682a86
API URL: JSON